MedTrace Logo

Advanced MR Imaging as Predictor of Treatment Response in Newly Diagnosed Glioblastomas

NCT02613988 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2024-05-14

No results posted yet for this study

Summary

This clinical trial studies advanced MR imaging techniques in measuring early response of standard treatment may become predictors of long-term treatment response in patients with newly diagnosed glioblastomas.

Conditions

  • Adult Glioblastoma

Interventions

DEVICE

3 Tesla magnetic resonance imaging

High resolution structural imaging (contrast-enhanced T1-weighted image, T2-weighted image, Fluid-attenuated inversion recovery)

DEVICE

Chemical exchange saturation transfer MRI

Amide proton transfer-weighted image

DEVICE

Diffusion weighted MRI

diffusion-weighted image with b value 0, 1000, and 3000

DEVICE

Dynamic susceptibility contrast MRI

dual echo EPI sequence

Sponsors & Collaborators

  • Asan Medical Center

    lead OTHER

Principal Investigators

  • Ho Sung Kim, MD, PhD · Asan Medical Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-12
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02613988 on ClinicalTrials.gov